Dear Duchenne Community, We are writing to provide some additional information to accompany our press release (attached) this week about the status of the rolling New Drug Application at the […]
Nomination package submitted to add Duchenne to the Recommended Uniform Screening Panel (RUSP) CureDuchenne is happy to share that Duchenne muscular dystrophy has been nominated to be added to the […]
Nomination package submitted to add Duchenne to the Recommended Uniform Screening Panel (RUSP) CureDuchenne is happy to share that Duchenne muscular dystrophy has been nominated to be added to the […]
CureDuchenne provided early and significant funding to Capricor Therapeutics for their Duchenne program, and we are pleased to share their latest updates. One-year results from their HOPE-2 open label extension […]
Italfarmaco released positive topline data from their Phase 3 trial in Givinostat, an anti-fibrotic for use in ambulant boys with Duchenne over 6 years old and on a chronic steroid […]
Significant decreases in key biomarkers of muscle damage.
We’re thrilled to announce that researchers at Nationwide Children’s Hospital have documented the first-ever creation of full-length dystrophin in a human as a response to gene therapy. CureDuchenne has contributed […]
Pfizer’s Global Clinical Lead for Rare Neurological Diseases, Beth Belluscio, MD-PhD, and Debra Miller, Founder and CEO of CureDuchenne, sat down to educate the Duchenne community on Pfizer’s CIFFREO Trial […]
